Variations in captopril formulations used to treat children with heart failure: a survey in the United Kingdom

Hussain Mulla, Magdi Tofeig, Frances Bu'Lock, Nilesh Samani and Hitesh C Pandya

Arch. Dis. Child. 2007;92;409-411; originally published online 15 Mar 2007; doi:10.1136/adc.2006.109389

Updated information and services can be found at:
http://adc.bmj.com/cgi/content/full/92/5/409

These include:

References
This article cites 6 articles, 1 of which can be accessed free at:
http://adc.bmj.com/cgi/content/full/92/5/409#BIBL

Rapid responses
You can respond to this article at:
http://adc.bmj.com/cgi/eletter-submit/92/5/409

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Archives of Disease in Childhood go to:
http://www.bmjjournals.com/subscriptions/
Variations in captopril formulations used to treat children with heart failure: a survey in the United kingdom

Hussain Mulla, Magdi Tofeig, Frances Bu’Lock, Nilesh Samani, Hitesh C Pandya

**Background and objective:** Different liquid formulations of a drug prepared for use in children cannot be assumed to have therapeutic equivalence. The objective of this study was to ascertain the interhospital constancy of unlicensed liquid captopril formulations used to treat children with heart failure in the UK.

**Design:** A questionnaire-based telephone survey.

**Setting:** 13 tertiary paediatric cardiac centres in the UK and 13 large hospitals referring patients to these centres.

**Participants:** The study included pharmacists responsible for providing the pharmaceutical input to children with congenital heart disease or a pharmacist designated to cover paediatric services. Technical staff employed by “specials” manufacturers also participated.

**Results:** Four hospitals dispensed captopril tablets for crushing and dissolving in water before administration; the remaining 22 used nine different liquid formulations of captopril. Only three cardiac centres and their referring hospitals were found to be using the same liquid captopril formulations; 10 centres and their referring hospitals were using completely different captopril formulations.

**Conclusions:** This survey shows that paediatric cardiac centres and their referring hospitals use a variety of unlicensed liquid captopril formulations interchangeably. This degree of inconsistency raises issues about optimal captopril dosing and potential toxicity, such that its use may influence paediatric cardiac surgical and interventional outcomes.

**METHODS**

Ethical approval was not required for this study.

**Identification of hospitals and data collection**

All tertiary paediatric congenital heart centres (those that perform paediatric cardiac surgery or therapeutic cardiac catheterisation) were identified and paired (except for Royal Victoria Hospitals, Belfast, UK) with hospitals (chosen arbitrarily) that referred patients to that centre. A telephone survey was then conducted by one of the authors (HM) with the clinical pharmacist responsible for providing the pharmaceutical input to children with congenital heart disease or a pharmacist designated to cover paediatric services. On some occasions, additional information was obtained from a pharmacist or technician responsible for formulations. Although each survey generally took no more than 15 min, occasionally repeat phone calls were necessary to obtain information not available at initial contact.

The questionnaire was designed to determine (1) whether the liquid captopril formulation dispensed by the hospital was procured from an external source (either a “specials” manufacturer or an NHS manufacturing unit) or extemporaneously prepared; (2) the identity of the external source; (3) whether the participants had any data on the consistency of the liquid formulation dispensed for patients by their hospital and community pharmacies; and (4) the nature of the extemporaneously prepared liquid formulations (excipients, shelf life and stability). Information regarding products procured from external sources was obtained by phoning the manufacturers’ technical departments.

**RESULTS**

Adequate responses to the questionnaire were obtained from all 13 tertiary paediatric cardiac centres and from 13 hospitals referring patients to these centres.

Four hospitals (three tertiary cardiac centres) dispensed captopril tablets for crushing and dissolving in water before administration; the remaining 22 used nine different liquid formulations of captopril (fig 1). Three of the liquid formulations...
were procured from “specials” manufacturers, one from an NHS manufacturing unit, four were extemporaneously prepared and one formulation was imported from Australia. This latter formulation is licensed in the source country, but is not currently available in the UK. The 13 tertiary cardiac centres were found to be using six different liquid preparations or to be crushing/dissolving tablets. In relation to the consistency of liquid formulation, only three cardiac centres and their referring hospitals were found to be using the same preparation; the remainder used completely different preparations. In addition, no hospital was found to have any data to support continued use of the captopril preparation dispensed by the hospital in the community. However, all but three hospitals provided letters detailing their source of the captopril liquid. The letters were given to the parents of the patients, who were asked to forward these letters to their doctor and/or community pharmacist. Three hospitals recommended formulations that were different from the formulation dispensed by the hospital.

Extemporaneous and “specials” formulations were either aqueous- or oil-based suspensions, or aqueous solutions, and were prepared using a range of excipients (table 1). The shelf life of “specials” formulations ranged from 1 to 3 months, whereas extemporaneously prepared formulations had a shelf life of 1–2 weeks. Apart from the Bristol–Myers Squibb formulation, no other manufacturer or hospital had conducted comprehensive stability studies on their final finished product to support the stated shelf life.

### DISCUSSION

This survey shows that paediatric cardiac centres and their referring hospitals use a variety of unlicensed liquid captopril formulations interchangeably to treat children with heart failure. Furthermore, informal discussions with hospital pharmacists suggest that it is possible that children with heart failure are dispensed one liquid captopril formulation by a

---

**Table 1** Composition and stability of liquid captopril formulations used to treat children with heart disease in the UK

<table>
<thead>
<tr>
<th>Formulation Type</th>
<th>Strengths</th>
<th>Expiry (days)</th>
<th>Stability data*</th>
<th>Excipients</th>
</tr>
</thead>
<tbody>
<tr>
<td>&quot;Specials” manufacturer</td>
<td>Various</td>
<td>90</td>
<td>No</td>
<td>Fractionated coconut oil, Cab-o-sil</td>
</tr>
<tr>
<td>Cardinal Health Martindale Products</td>
<td></td>
<td></td>
<td></td>
<td>Xanthan gum 1%, ascorbic acid</td>
</tr>
<tr>
<td>Nova Laboratories (flavoured)</td>
<td>Various</td>
<td>28</td>
<td>No</td>
<td>Flavoured suspension Diluent A in a 1:1 ratio with water</td>
</tr>
<tr>
<td>Nova Laboratories (unflavoured)</td>
<td>Various</td>
<td>28</td>
<td>No</td>
<td>Suspension diluent A in a 1:1 ratio with water</td>
</tr>
<tr>
<td>NHS manufacturing unit</td>
<td>1, 5 and 12.5 mg/ml</td>
<td>35</td>
<td>No</td>
<td>Xanthan gum 0.4%, methyl hydroxybenzoate, propyl-hydroxy benzoate</td>
</tr>
<tr>
<td>(St Mary’s Pharmaceutical Unit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imported</td>
<td>5 mg/ml</td>
<td>28</td>
<td>Yes</td>
<td>Citric acid, sodium citrate, disodium edetate, sodium benzoate</td>
</tr>
<tr>
<td>Extemporaneous formulations</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Southamptom General Hospital</td>
<td>1 mg/ml</td>
<td>14</td>
<td>No</td>
<td>Ascorbic acid, water</td>
</tr>
<tr>
<td>Bradford Royal Infirmary, Royal Hospitals, Belfast, and St George’s, London</td>
<td>Various</td>
<td>14</td>
<td>No</td>
<td>Suspension diluent A</td>
</tr>
<tr>
<td>St George’s, London</td>
<td>Various</td>
<td>14</td>
<td>No</td>
<td>OraPlus/OraSweet (1:1 ratio)</td>
</tr>
<tr>
<td>Queen’s Medical Centre, Nottingham, and Gloucester Royal Infirmary</td>
<td>Various</td>
<td>14</td>
<td>No</td>
<td>Suspension diluent A in a 1:1 ratio with water</td>
</tr>
</tbody>
</table>

Suspension diluent A contains xanthan gum 1%, methyl hydroxybenzoate and propylhydroxy benzoate. St George’s Hospital, London, provided two extemporaneous methodologies.

*Evidence of comprehensive in-house stability data on the final finished product.
hospital pharmacy and a completely different formulation by a community pharmacy.

Using different licensed formulations of a drug interchangeably is common and accepted practice where bioequivalence data are available. In relation to captopril and paediatric heart failure, no bioequivalence data exist for the liquid formulations identified in this survey. Hence, it is not possible to be confident that the rate and extent of captopril absorption do not vary according to its formulation. Not surprisingly, the manufacturers of liquid captopril do not guarantee that their formulation performs in vivo, just that their manufacturing process adheres to a quality assurance system.

Therapeutic equivalence between differing formulations should not be assumed, as excipients can significantly affect the rate and extent of drug absorption. For example, it is conceivable that the performance in vivo of an oil-based suspension will not be the same as that of an aqueous-based suspension. The practice of crushing tablets and dissolving in water adopted by some centres may be even worse than using unlicensed formulations, as crushing tablets has the potential for dose inaccuracies as well as altered absorption. Such practice is also associated with the highest risk of errors, as there is no record or control of preparation.

Taken together, these issues strongly argue against using unlicensed liquid formulations of captopril interchangeably, as seems to be the case in many UK regions. The present lack of consistency in liquid captopril formulations dispensed to children with heart disease raises issues about efficacy and toxicity. Moreover, failure to optimise captopril treatment in children with heart failure has potential repercussions for both immediate and long-term surgical outcomes, as many children require further and often multiple surgical interventions.

Treatment outcomes for children with heart disease are scrutinised by the Department of Health and various Royal Colleges. However, variances in outcomes owing to drug treatment have received scant attention either by these institutions or by paediatric cardiac specialists. Even less attention has been paid to the influence of using unlicensed drug formulations, interchangeably, on these outcomes. It is estimated that, annually, up to 1000 children will be initiated on captopril for the treatment of heart failure. To ensure optimal treatment, we recommend that: 1) doctors/hospital pharmacies and community colleagues use identical formulations; 2) medicines regulatory authorities and pharmaceutical manufacturers work together to ensure that liquid captopril formulations with supporting bioequivalence data are developed.

What is already known on this topic

- The lack of suitable oral formulations of medicines for children is often overcome by preparing or procuring unlicensed liquids.
- Such unlicensed formulations are deemed necessary, while accepting that their clinical reliability and performance has not been tested and that their relative bioavailability is unknown.

What this study adds

- A wide variety of unlicensed and untested liquid captopril formulations is used interchangeably in the treatment of children with heart failure.
- This degree of inconsistency raises issues about optimal captopril dosing and potential toxicity, such that its use may influence paediatric cardiac surgical and interventional outcomes.

Authors’ affiliations

Hussain Mulla, Centre for Pharmacy Practice Research, Glenfield Hospital, Leicester, UK
Magdi Tofeig, Frances Bu’Lock, Hitesh C Pandya, Congenital and Paediatric Heart Service, Glenfield Hospital, Leicester, UK
Nilesh Samani, British Heart Foundation, Department of Cardiovascular Sciences, University of Leicester, Glenfield General Hospital, Leicester, UK

Competing interests: None.

REFERENCES